#186 - Patrick Radden Keefe: The opioid crisis—origin, guilty parties, and the difficult path forward

Episode Summary

Executive Summary: Peter Atiyah interviews Patrick Radden Keefe about the opioid epidemic, focusing on how Purdue Pharma and the Sackler family helped ignite and sustain it through aggressive marketing, regulatory capture, and denial. The conversation traces the drug’s origins, the FDA approval process, the role of physicians and distributors, and the moral and legal failures that allowed a public health catastrophe to unfold.

Main Topics: Origins of the opioid crisis and Purdue’s central role (Priority: 5/5): Keefe argues that while many actors contributed, Purdue Pharma’s OxyContin was the key catalyst that expanded opioid prescribing and helped create the market that later shifted to heroin and fentanyl. The Sackler family and Purdue’s business model (Priority: 5/5): The discussion covers the Sackler brothers’ rise, their pharmaceutical marketing genius, and how a privately held family company enabled long-term control with limited accountability. FDA approval, soft corruption, and regulatory capture (Priority: 5/5): The episode details how Purdue worked closely with FDA official Curtis Wright, blurring lines between regulator and company and enabling favorable labeling and approval claims. Marketing pain as a market expansion strategy (Priority: 4/5): Keefe explains how Purdue reframed OxyContin from a cancer-pain drug into a treatment for broad chronic pain, using the idea that pain was undertreated and that doctors needed education. Evidence of early abuse and company denial (Priority: 5/5): The conversation highlights that Purdue knew early on about abuse, overdose, and diversion, yet publicly denied problems and continued aggressive sales tactics. Bankruptcy, settlements, and accountability (Priority: 4/5): The episode examines Purdue’s bankruptcy, the Sacklers’ proposed settlement, and the controversial third-party release that could shield the family from future lawsuits. Personal and clinical reflections on opioid dependence (Priority: 4/5): Atiyah shares his own experience with OxyContin dependence after surgery, reinforcing the episode’s point that legitimate medical exposure can rapidly lead to physiological dependence and harm.

Key Arguments: Purdue Pharma was not the only cause of the opioid crisis, but OxyContin was the pivotal product that changed prescribing norms and expanded the market for opioids. The Sacklers’ privately held structure allowed them to keep control, extract wealth, and avoid the kind of board and leadership turnover that a public company might have faced. Purdue’s marketing strategy depended on exploiting the stigma around morphine and the belief that OxyContin’s time-release design made it less addictive, despite lacking abuse-liability testing. Regulatory approval was compromised by close, informal interactions between Purdue and FDA official Curtis Wright, suggesting at minimum soft corruption and possibly a quid pro quo. Purdue knew early that OxyContin was being abused, crushed, sold on the street, and linked to overdoses, but executives later denied awareness under oath. The company and its allies helped shape pain policy and medical culture, including the “fifth vital sign” movement and broad pain-management education efforts. The 2007 federal case was weakened when DOJ leadership removed felony charges, preventing executives from being pressured to implicate the Sacklers. The current bankruptcy settlement may provide some compensation, but it is unlikely to match the scale of harm or create strong deterrence unless individuals face jail time. The crisis has evolved from prescription opioids to heroin and fentanyl, but that does not erase the role prescription opioids played in initiating many users. Overcorrection is a real risk: restricting pain medication too aggressively could harm legitimate patients, but that concern does not negate Purdue’s wrongdoing.

Data Points: Deaths from opioid overdose: At least 500,000 in the past 25 years - Used to frame the scale of the epidemic in the U.S. Americans with opioid use disorder: 2+ million - Estimate cited during discussion of the current burden of addiction. Purdue guilty plea and fine: $600 million fine in 2007 - Company pleaded guilty to felony misbranding charges. Sackler wealth extraction: More than $10 billion - Amount the family allegedly took out of Purdue over about a decade after the 2007 plea. Proposed Sackler settlement: $4.5 billion over 9 years - Amount the family offered in bankruptcy to resolve claims and obtain releases. Sackler remaining fortune: About $11 billion - Discussed in relation to the proposed settlement and ability to preserve wealth. OxyContin 80 mg sales decline after reformulation: 25% drop - Internal study cited after the abuse-deterrent reformulation rolled out in 2010. Purdue sales force: About 700 sales reps - Used to describe the scale of the company’s physician marketing operation. MSContin revenue at peak: $300–400 million per year - Illustrates Purdue’s earlier success before OxyContin became the blockbuster. Creedmoor Psychiatric Hospital capacity: About 6,000 beds - Referenced while describing the brothers’ early psychiatric training environment. Pediatric indication extension: 6 months of additional patent exclusivity - Explains why Purdue pursued a pediatric indication for OxyContin. OxyContin launch: Early 1996 - The drug’s retail introduction date discussed in the interview. Time to reformulation: 2010 - Year Purdue rolled out the crush-resistant reformulated OxyContin. OxyContin dose in Atiyah’s personal story: From 40 mg/day to nearly 400 mg/day in four months - Personal anecdote illustrating rapid tolerance and dependence.

Pivotal Quotes: "OxyContin was sort of the, in the words of somebody who worked on the drug, was the tip of the spear." — Patrick Radden Keefe: Explaining why Purdue and OxyContin are central to understanding the broader opioid crisis. "The package insert in a bottle of pills is our most potent selling instrument." — Richard Sackler (quoted by Keefe): Illustrates how the company viewed labeling and regulatory language as marketing tools. "I think a deal was made." — Former federal prosecutor (quoted by Patrick Radden Keefe): Referring to Curtis Wright’s move from FDA to Purdue and the suspected quid pro quo.

Implications: The episode argues that the opioid crisis was not an accident but a product of incentives, weak oversight, and institutional capture. It warns that meaningful deterrence likely requires individual accountability, while also preserving access for legitimate pain patients.